Research by Neeraj Agarwal, MD, called TALAPRO-2 showed that taking TALZENNA along with XTANDI can lower the risk of mortality or disease progression related to prostate cancer by 37%. At the American Society of Clinical Oncology Genitourinary Cancers Conference last month, Agarwal, who holds the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Center, gave a presentation on the findings of one of his numerous Phase III trials.
Prostate cancer is the most prevalent cancer and the second highest cause of cancer death in males in the United States, according to the National Cancer Institute. Prostate cancer that is advanced and resistant to androgen blocking is known as castration-resistant prostate cancer or CRPC.
To treat metastatic prostate cancer, TALAPRO-2 combines the two oral medicines TALZENNA and XTANDI. The experiment examines the efficacy of combining TALZENNA with the commonly prescribed androgen receptor blocker XTANDI, which stops male hormones from fueling the tumor. A PARP inhibitor called TALZENNA is frequently used to treat breast cancer.
Each participant’s treatment plan in the overall trial had a randomly chosen course of action. While some patients received the two medications together, others received the usual dosage of XTANDI and a placebo. The clinical trials team at the Huntsman Cancer Center was crucial in keeping track of the patients who were registered at the facility. All Phase III trials must compare side effects and outcomes between the two groups as a crucial component.
“As a physician, I want my patients to be able to enjoy life while being treated for cancer,” says Agarwal. “Clinical trials help us find better cancer treatments with fewer side effects. Those who are impacted by cancer can have hope that their treatment is constantly improving.
Phase IIIĀ trialsĀ are the last phase before the FDA can approve a new treatment. The FDA decision on this investigatory drug combination is expected in 2023.
more recommended stories
-
FDA Approves Duvyzat Medicine to treat Duchenne Muscular Dystrophy
Duvyzat (givinostat) oral medication was approved.
-
Novel Technique for Human Artificial Chromosomes
Human artificial chromosomes (HACs), with the.
-
Breast Cancer Treatment: AI Tool Predicts Side Effect Risks
An artificial intelligence (AI) tool created.
-
Synthetic Biology: Enhancing Nutritional Value, Color, and Flavor
In a recent publication featured in.
-
COVID-19 Over-the-Counter Medication Considerations
The COVID-19 virus can cause symptoms.
-
FDA Approves Rezdiffra Drug to Treat Liver Disease
Rezdiffra (resmetirom) was approved today by.
-
Culinary Herbs and Spices with Polyphenols – Enhancing Gut Health
In a recent publication in the.
-
Tandem Cycling Enhances Well-Being for Parkinson’s Patients and Care Partners
Tandem cycling holds the promise of.
-
Bariatric surgery is an Effective Tool for Managing Diabetes
Bariatric surgery is more beneficial than.
-
Drug can Reduce Harmful Reactions to Foods causing Allergy
A medication can make life safer.
Leave a Comment